NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jul 5

PMID 22761704

Citations 41

Authors

Foluso O Ademuyiwa

Wiam Bshara

Kristopher Attwood

Carl Morrison

Stephen B Edge

Adam R Karpf

Smith A James

Christine B Ambrosone

Tracey L OConnor

Ellis G Levine

Anthony Miliotto

Erika Ritter

Gerd Ritter

Sacha Gnjatic

Kunle Odunsi

Affiliations

Soon will be listed here.

Abstract

Purpose: NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of expression by immunohistochemistry (IHC) and the degree of inherent immunogenicity to NY-ESO-1.

Experimental Design: 168 TNBC and 47 ER+/HER2- primary breast cancer specimens were used to determine NY-ESO-1 frequency by IHC. As previous studies have shown that patients with a robust innate humoral immune response to CT antigens are more likely to develop CD8 T-cell responses to NY-ESO-1 peptides, we evaluated the degree to which patients with NY-ESO-1 expression had inherent immunogenicity by measuring antibodies. The relationship between NY-ESO-1 expression and CD8+ T lymphocytes was also examined.

Results: The frequency of NY-ESO-1 expression in the TNBC cohort was 16% versus 2% in ER+/HER2- patients. A higher NY-ESO-1 score was associated with a younger age at diagnosis in the TNBC patients with NY-ESO-1 expression (p = 0.026). No differences in OS (p = 0.278) or PFS (p = 0.238) by NY-ESO-1 expression status were detected. Antibody responses to NY-ESO-1 were found in 73% of TNBC patients whose tumors were NY-ESO-1 positive. NY-ESO-1 positive patients had higher CD8 counts than negative patients (p = 0.018).

Conclusion: NY-ESO-1 is expressed in a substantial subset of TNBC patients and leads to a high humoral immune response in a large proportion of these individuals. Given these observations, patients with TNBC may benefit from targeted therapies directed against NY-ESO-1.

Citing Articles

An immunoinformatics approach for a potential NY-ESO-1 and WT1 based multi-epitope vaccine designing against triple-negative breast cancer.

Khanam A, Hridoy H, Alam M, Sultana A, Hasan I Heliyon. 2024; 10(17):e36935.

PMID: 39286192 PMC: 11402771. DOI: 10.1016/j.heliyon.2024.e36935.

Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study.

Forchhammer S, Pop O, Hahn M, Aebischer V, Seitz C, Schroeder C Virchows Arch. 2024; 485(2):335-346.

PMID: 38890171 PMC: 11329550. DOI: 10.1007/s00428-024-03846-0.

Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.

ceprnja T, Tomic S, Peric Balja M, Marusic Z, Blazicevic V, Spagnoli G Int J Mol Sci. 2024; 25(8).

PMID: 38674098 PMC: 11050590. DOI: 10.3390/ijms25084513.

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.

Rivoltini L, Camisaschi C, Fuca G, Paolini B, Vergani B, Beretta V Sci Rep. 2024; 14(1):3379.

PMID: 38336861 PMC: 10858221. DOI: 10.1038/s41598-024-54041-9.

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential.

Chamorro D, Somes L, Hoyos V Cancers (Basel). 2024; 16(1).

PMID: 38201551 PMC: 10778447. DOI: 10.3390/cancers16010124.

References

Del Rio M, Penuelas-Rivas G, Dominguez-Perles R, Ramirez P, Parrilla P, Rodriguez-Barbosa J . Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. Eur J Immunol. 2005; 35(12):3545-60. DOI: 10.1002/eji.200535232. View

Grigoriadis A, Caballero O, Hoek K, Da Silva L, Chen Y, Shin S . CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A. 2009; 106(32):13493-8. PMC: 2716388. DOI: 10.1073/pnas.0906840106. View

Shin T, Yoshimura K, Shin T, Crafton E, Tsuchiya H, Housseau F . In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med. 2005; 201(10):1531-41. PMC: 2212923. DOI: 10.1084/jem.20050072. View

STOCKERT E, Jager E, Chen Y, Scanlan M, Gout I, Karbach J . A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998; 187(8):1349-54. PMC: 2212223. DOI: 10.1084/jem.187.8.1349. View

West N, Milne K, Truong P, Macpherson N, Nelson B, Watson P . Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011; 13(6):R126. PMC: 3326568. DOI: 10.1186/bcr3072. View

Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A . LAGE-1, a new gene with tumor specificity. Int J Cancer. 1998; 76(6):903-8. DOI: 10.1002/(sici)1097-0215(19980610)76:6<903::aid-ijc22>3.0.co;2-1. View

Gnjatic S, Ritter E, Buchler M, Giese N, Brors B, Frei C . Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010; 107(11):5088-93. PMC: 2841879. DOI: 10.1073/pnas.0914213107. View

Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt J . Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010; 222(4):350-66. PMC: 3033700. DOI: 10.1002/path.2774. View

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E . Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31):12837-42. PMC: 1937553. DOI: 10.1073/pnas.0703342104. View

10.

Chen Y, Ross D, Chiu R, Zhou X, Chen Y, Lee P . Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One. 2011; 6(3):e17876. PMC: 3060908. DOI: 10.1371/journal.pone.0017876. View

11.

Theurillat J, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B . NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer. 2007; 120(11):2411-7. DOI: 10.1002/ijc.22376. View

12.

Urban J, Schreiber H . Tumor antigens. Annu Rev Immunol. 1992; 10:617-44. DOI: 10.1146/annurev.iy.10.040192.003153. View

13.

Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki N . Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003; 100(15):8862-7. PMC: 166404. DOI: 10.1073/pnas.1133324100. View

14.

Jager E, Nagata Y, Gnjatic S, Wada H, STOCKERT E, Karbach J . Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A. 2000; 97(9):4760-5. PMC: 18306. DOI: 10.1073/pnas.97.9.4760. View

15.

Ambrosone C, Nesline M, Davis W . Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol Biomarkers Prev. 2006; 15(9):1575-7. DOI: 10.1158/1055-9965.EPI-06-0628. View

16.

Horne Z, Jack R, Gray Z, Siegfried J, Wilson D, Yousem S . Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011; 171(1):1-5. DOI: 10.1016/j.jss.2011.03.068. View

17.

Hofmann O, Caballero O, Stevenson B, Chen Y, Cohen T, Chua R . Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008; 105(51):20422-7. PMC: 2603434. DOI: 10.1073/pnas.0810777105. View

18.

Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C . A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010; 116(17):4043-53. PMC: 2930033. DOI: 10.1002/cncr.25204. View

19.

Mischo A, Kubuschok B, Ertan K, Preuss K, Romeike B, Regitz E . Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer. 2005; 118(3):696-703. DOI: 10.1002/ijc.21352. View

20.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View